Providing Early Access Program of Neratinib for HER2-Positive (HER2+) Breast Cancer
Providing Early Access Program of Neratinib for HER2-Positive (HER2+) Breast Cancer
  • Michael Kim/Singapore
  • 승인 2018.04.08 01:50
  • 댓글 0
이 기사를 공유합니다

[SINGAPORE] Specialised Therapeutics Asia announced on April 5 that the initiation of an early access program for neratinib, an extended adjuvant treatment for early-stage HER2-positive (HER2+) breast cancer.

According to PR Newswire, Under this Special Access Program (SAP)  select patients in Australia will be provided access to the medicine, where appropriate and when permitted by relevant regulatory authorities.

The SAP protocol allows for neratinib to be available to patients with HER2 overexpressing cancers.

In all cases, the patient must have a special clinical need that cannot be met by currently approved and available medicines.

Specialised Therapeutics' neratinib Special Access Program follows the signing of a key license agreement with Puma Biotechnology Inc. in November 2017, providing exclusive rights to commercialise neratinib in Australia, New Zealand and in South East Asia.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • ABOUT
  • CONTACT US
  • SIGN UP MEMBERSHIP
  • RSS
  • 2-D 678, National Assembly-daero, 36-gil, Yeongdeungpo-gu, Seoul, Korea (Postal code: 07257)
  • URL: www.koreaittimes.com | Editorial Div: 82-2-578- 0434 / 82-10-2442-9446 | North America Dept: 070-7008-0005 | Email: info@koreaittimes.com
  • Publisher and Editor in Chief: Monica Younsoo Chung | Chief Editorial Writer: Hyoung Joong Kim | Editor: Yeon Jin Jung
  • Juvenile Protection Manager: Choul Woong Yeon
  • Masthead: Korea IT Times. Copyright(C) Korea IT Times, All rights reserved.
ND소프트